Technical Analysis for GWPH - GW Pharmaceuticals Plc
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Very Strong | Up | Up | Flat |
| Historical GWPH trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Gilligan's Island Sell Setup | Bearish Swing Setup | 3.56% | |
| New 52 Week Closing High | Bullish | 3.56% | |
| Pocket Pivot | Bullish Swing Setup | 3.56% | |
| Volume Surge | Other | 3.56% | |
| Calm After Storm | Range Contraction | 3.56% | |
| New 52 Week High | Strength | 3.56% | |
| Parabolic Rise | Strength | 3.56% | |
| 1,2,3 Pullback Bullish | Bullish Swing Setup | 49.68% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 49.68% | |
| Calm After Storm | Range Contraction | 49.68% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Trending on StockTwits | about 9 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 05/10/2021
GW Pharmaceuticals Plc Description
GW Pharmaceuticals plc, together with its subsidiaries, engages in the research, development, and commercialization of a range of cannabinoid prescription medicines. The company primarily offers Sativex, an oromucosal spray for the treatment of MS symptoms, cancer pain, and neuropathic pain. It also focuses on the Phase III clinical development program of Sativex for use in treatment of cancer pain. In addition, the company has two product candidates in Phase II trials in the field of diabetes and inflammation, as well as pre-clinical research programmes evaluating the use of selected cannabinoids for the treatment of glioma, epilepsy, and psychiatric illness. It has a strategic alliance with Otsuka Pharmaceutical Co. Ltd. The company operates in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc was founded in 1998 and is based in Salisbury, the United Kingdom.
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Major
Keywords: Cancer Pharmaceutical Industry Clinical Development Pain Drugs Treatment Of Cancer Diabetes Medication Inflammation Cannabis Clinical Research Symptoms Epilepsy Neuropathic Pain Cannabinoid Glioma Cannabinoids Medical Cannabis Research Treatment Of Ms
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 219.0 |
| 52 Week Low | 87.07 |
| Average Volume | 873,069 |
| 200-Day Moving Average | 141.99 |
| 50-Day Moving Average | 215.66 |
| 20-Day Moving Average | 217.37 |
| 10-Day Moving Average | 218.03 |
| Average True Range | 1.24 |
| ADX | 56.26 |
| +DI | 30.59 |
| -DI | 9.19 |
| Chandelier Exit (Long, 3 ATRs ) | 215.27 |
| Chandelier Exit (Short, 3 ATRs ) | 217.84 |
| Upper Bollinger Band | 219.64 |
| Lower Bollinger Band | 215.09 |
| Percent B (%b) | 0.84 |
| BandWidth | 2.09 |
| MACD Line | 2.38 |
| MACD Signal Line | 2.99 |
| MACD Histogram | -0.6162 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 219.87 | ||||
| Resistance 3 (R3) | 219.79 | 219.40 | 219.71 | ||
| Resistance 2 (R2) | 219.40 | 219.15 | 219.43 | 219.65 | |
| Resistance 1 (R1) | 219.15 | 219.00 | 219.27 | 219.22 | 219.60 |
| Pivot Point | 218.75 | 218.75 | 218.81 | 218.79 | 218.75 |
| Support 1 (S1) | 218.50 | 218.51 | 218.63 | 218.58 | 218.20 |
| Support 2 (S2) | 218.11 | 218.35 | 218.14 | 218.15 | |
| Support 3 (S3) | 217.86 | 218.11 | 218.09 | ||
| Support 4 (S4) | 217.93 |
